about
Progress in corneal wound healingLoss of endogenous thymosin β4 accelerates glomerular disease.Emerging drugs for the treatment of dry eye disease.Advances in the basic and clinical applications of thymosin β4.A peptide from human β thymosin as a platform for the development of new anti-biofilm agents for Staphylococcus spp. and Pseudomonas aeruginosa.Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury.Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves -Induced Keratitis
P2860
Q28081311-3850DA8C-40EF-4B1F-B144-9E42D6554B08Q37354989-43742050-E41F-42DE-96F5-804C73D9B61DQ38102006-E47FCAD6-1C6C-4755-A298-69B97A7B910FQ38533845-BF29B9E8-9FD3-477E-88B1-49FE271E5F3BQ40638419-A6868445-8BDC-44BF-B2E4-34EB0968CFEBQ42073404-CA71A011-DB63-4F17-A219-BFDB900C36EDQ58708678-0B0E0552-6C08-49BC-9C12-BF9637502679
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Thymosin β4: a potential novel dry eye therapy.
@en
type
label
Thymosin β4: a potential novel dry eye therapy.
@en
prefLabel
Thymosin β4: a potential novel dry eye therapy.
@en
P2093
P2860
P1476
Thymosin β4: a potential novel dry eye therapy.
@en
P2093
David Crockford
Gabriel Sosne
George W Ousler
Steven P Dunn
P2860
P356
10.1111/J.1749-6632.2012.06682.X
P407
P577
2012-10-01T00:00:00Z